Reuters logo
BRIEF-Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial
2016年10月14日 / 晚上9点27分 / 1 年前

BRIEF-Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial

Oct 14 (Reuters) - Osiris Therapeutics Inc

* says on October 14, 2016, company commenced steps to terminate enrollment in its OTI-15-01 phase III clinical trial

* Osiris -trial was investigating safety and efficacy of OTI-15-01 in patients suffering from chronic DFUS that have not responded to standard of care therapy

* Osiris -patients currently enrolled in trial will continue with their current course of treatment and scheduled visit assessments, as outlined in protocol

* Osiris -decision to terminate reflects co's desire to allocate more of its research, development resources to other clinical programs-SEC filing Source text for Eikon: (bit.ly/2epHgdQ) Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below